Oslo, 6 May 2026 - Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-
the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the
treatment of solid cancers, today announces that the first clinical site in the
ZIMA-101 Phase 1 trial has now been activated.
This marks the transition of the study from clinical preparation to active trial
execution of the ZIMA-101 study.
The first activated clinical site is The Christie NHS Foundation Trust in the
United Kingdom, where Professor Fiona Thistlethwaite serves as Chief
Investigator for the study.
ZIMA-101 is a first-in-human Phase 1 trial evaluating ZI-MA4-1, Zelluna's lead
TCR-NK product candidate.
On 20 February 2026, Zelluna announced that the Medicines and Healthcare
products Regulatory Agency (MHRA) and Research Ethics Committee (REC) had
approved the Company's Clinical Trial Application (CTA) for ZIMA-101 in the UK.
Activation of the second clinical site, The Royal Marsden, is expected in the
near term.
"This is an important milestone for Zelluna. With the first clinical site now
activated, we are entering the execution phase of the ZIMA-101 study. Our focus
is now on advancing clinical execution, including patient screening and
progression toward first patient dosing" says CEO Namir Hassan.
Zelluna has previously communicated that initial clinical data from the ZIMA-
101 study are expected to emerge from mid-2026.
For further information, please visit www.zelluna.com
(http://www.zelluna.com/) or contact:
Namir Hassan, CEO
Email: namir.hassan@zelluna.com (mailto:namir.hassan@zelluna.com)
Phone: +44 7720 687608
Geir Christian Melen, CFO
Email: geir.christian.melen@zelluna.com
(mailto:geir.christian.melen@zelluna.com)
Phone: +47 913 02 965
About Zelluna ASA
Zelluna ASA (OSE: ZLNA) is a pioneering allogeneic 'off-the-shelf' T Cell
Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers.
The company's platform combines the innate killing power of NK cells with
precise solid tumour targeting of TCRs, designed to address the limitations of
current cell therapies in solid tumours. The company's lead candidate, ZI-MA4-
1, is the world's first MAGE-A4 targeting TCR-NK therapy in clinical
development. Zelluna is headquartered at the Oslo Cancer Cluster Innovation Park
in Oslo, Norway and is listed on the Oslo Stock Exchange under the ticker ZLNA.